<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819958</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-B01</org_study_id>
    <nct_id>NCT04819958</nct_id>
  </id_info>
  <brief_title>The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer</brief_title>
  <official_title>The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Short-term Outcome and Long-term Outcome of Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effect of immunological heterogeneity of tumor&#xD;
      microenvironment in the short-term outcome and long-term outcome of patients with gastric&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective cohort study will be performed to explore the effect of immunological&#xD;
      heterogeneity of tumor microenvironment in the short-term outcome and long-term outcome of&#xD;
      patients with gastric cancer. The evaluation parameters are perioperative clinical efficacy,&#xD;
      postoperative complications, and 3-year survival and recurrence rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year disease free survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rates</measure>
    <time_frame>30 days</time_frame>
    <description>This is for the incidence of early postoperative complications, which defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>30 days</time_frame>
    <description>This is for the early mortality, which defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of retrieved lymph nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Total number of retrieved lymph nodes after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative morbidity rates</measure>
    <time_frame>1 day</time_frame>
    <description>The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of white blood cell count</measure>
    <time_frame>Preoperative 7 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of hemoglobin</measure>
    <time_frame>Preoperative 7 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of C-reactive protein</measure>
    <time_frame>Preoperative 7 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of C-reactive protein in milligram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into four categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, and mixed type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first flatus in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first liquid diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first soft diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first soft diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stomach Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      the resected specimens with DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are assigned to undergo gastrectomy for gastric cancer are included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 80 years&#xD;
&#xD;
          2. Histology confirmed gastric adenocarcinoma (papillary, tubular, mucinous, signet ring&#xD;
             cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy.&#xD;
&#xD;
          3. Clinical stage: cTNM: stage I or above at preoperative evaluation according to the&#xD;
             American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition&#xD;
&#xD;
          4. Performance status: Eastern Cooperative Oncology Group (ECOG) â‰¤ 2 (normal to&#xD;
             symptomatic but in bed less than half the day)&#xD;
&#xD;
          5. Clinically fit for gastric cancer surgery, i.e. adequate renal, hepatic, hematologic,&#xD;
             and pulmonary function.&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women during pregnancy or breast-feeding&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. History of previous gastrectomy, endoscopic mucosal resection, or endoscopic&#xD;
             submucosal dissection&#xD;
&#xD;
          4. History of other malignant diseases within the past five years&#xD;
&#xD;
          5. History of unstable angina or myocardial infarction within the past six months&#xD;
&#xD;
          6. History of a cerebrovascular accident within the past six months&#xD;
&#xD;
          7. History of continuous systematic administration of corticosteroids within one month&#xD;
&#xD;
          8. Requirement of simultaneous surgery for other diseases&#xD;
&#xD;
          9. Emergency surgery due to complication (bleeding, obstruction, or perforation) caused&#xD;
             by gastric cancer&#xD;
&#xD;
         10. Forced expiratory volume in 1 second (FEV1)&lt;50% of predicted values&#xD;
&#xD;
         11. Inclusion in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Changming Huang, MD</last_name>
    <phone>+8613805069676</phone>
    <email>hcmlr2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhong</last_name>
    <phone>+8615859634839</phone>
    <email>845733977@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastric Surgery</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Ming Huang, MD</last_name>
      <phone>+8613805069676</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31.</citation>
    <PMID>32868929</PMID>
  </reference>
  <reference>
    <citation>Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5. Review.</citation>
    <PMID>32861308</PMID>
  </reference>
  <reference>
    <citation>Utzschneider DT, Gabriel SS, Chisanga D, Gloury R, Gubser PM, Vasanthakumar A, Shi W, Kallies A. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat Immunol. 2020 Oct;21(10):1256-1266. doi: 10.1038/s41590-020-0760-z. Epub 2020 Aug 24.</citation>
    <PMID>32839610</PMID>
  </reference>
  <reference>
    <citation>Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, Fan Y, Chan NT, Ma L, Liu J, Wang D, Dai X, Liu H, Ono M, Nakanishi A, Inuzuka H, North BJ, Huang YH, Sharma S, Geng Y, Xu W, Liu XS, Li L, Miki Y, Sicinski P, Freeman GJ, Wei W. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020 Sep;22(9):1064-1075. doi: 10.1038/s41556-020-0562-4. Epub 2020 Aug 24.</citation>
    <PMID>32839551</PMID>
  </reference>
  <reference>
    <citation>Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur Urol. 2020 Oct;78(4):498-502. doi: 10.1016/j.eururo.2020.07.011. Epub 2020 Aug 19.</citation>
    <PMID>32828600</PMID>
  </reference>
  <reference>
    <citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.</citation>
    <PMID>25428505</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Director, Head of Department of Gastric Surgery, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

